An Experimental Lilly Cancer Drug Misses A Lucrative Target

In a setback to Eli Lilly, a late-stage study found that a closely watched experimental drug failed to meet its primary endpoint in combating breast cancer. Although expectations on Wall Street had al…
Read the full story: Pharmalot